Trial By Error: An Interview with Neuroscientist Michael VanElzakker about the Just-Published and Long-Awaited NIH Study
https://virology.ws/2024/02/28/tria...he-just-published-and-long-awaited-nih-study/
Thanks for posting
@Andy and thanks for the interview
@dave30th. It's good to get some perspective on how VanElzakker would like to see this study used in further processes in the public and what framing should be used in the public. It's good to hear that he also sees a large discrepancy in data vs its interpretation and that he, as a neuroscientist, "cringed" about the RTJ "findings".
The message I got from VanElzakker was something along the lines of "If they say there's a persistent antigen and T-cell exhaustion, then let's demand studies doing T-cell sequencing to find out what these T-cells are responding to".
Unfortunately, one often seen study results not being followed up at all (or if they were, negative results weren't being published), so I'm a bit more pessimistic for how much one can push for based on these results, but as
@RaviHVJ has said this is where focus should be put. I don't know which levers have to be pressed at which levels to ensure some sort of positive momentum, but I'm sure that many of those people in the position to control those levers won't be reading the study at much detail or at all.
I suppose a larger problem that occurs when pushing for a direct follow-up on the "results" of the paper, for instance T-cell sequencing to find what these are responding too, is that this won't be the answer, if there is no data to support it in the first place and if it was all just interpretation. So this will have to be somehow cleverly managed in terms of demanding direct studies/trials based on things supposedly found in the study, because it's more actionable and easier to do, but at the same time demanding things that are far more general and are actually useful, so something such as an increased funding for immunological studies that also include T-cell sequencing, i.e. carefully demanding actionability by accounting for the usefulness of certain follow-up's.
What could we demand based on these results (even if they are all interpretation) and what should we demand?
Apart from the various people dedicating their time here meticulously analysing the study and data, it is of some importance to understand on "how things should be played politically" in the media and at NIH level, something I definitely don't have the faintest of clues about. I do think if the general public would be reading the news articles on the study they'd be more inclined to think that this is a serious biological illness rather than the opposite, independently of whether the paper is supported by its own data.
I think a discussion along those lines and especially the interview, is all of relevance for those planning to write, or writing letters to Nath, the NIH director Bertagnolli and other people, which is currently being discussed in a seperate thread
here.